A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

BACKGROUND: Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Heng, Liu, Xiaofan, Li, Yan, Zhou, Hu, Feng, Ying, Gao, Guangxun, Cheng, Peng, Huang, Ruibin, Yang, Linhua, Hu, Jianda, Hou, Ming, Yao, Yazhou, Liu, Li, Wang, Yi, Wu, Depei, Zhang, Liansheng, Zheng, Changcheng, Shen, Xuliang, Hu, Qi, Liu, Jing, Jin, Jie, Luo, Jianmin, Zeng, Yun, Gao, Sujun, Zhang, Xiaohui, Zhou, Xin, Shi, Qingzhi, Xia, Ruixiang, Xie, Xiaobao, Jiang, Zhongxing, Gao, Li, Bai, Yuansong, Xiong, Junye, Li, Runzi, Zou, Jianjun, Niu, Ting, Yang, Renchi, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905908/
https://www.ncbi.nlm.nih.gov/pubmed/33632264
http://dx.doi.org/10.1186/s13045-021-01047-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905908/
https://www.ncbi.nlm.nih.gov/pubmed/33632264
http://dx.doi.org/10.1186/s13045-021-01047-9

Ejemplares similares